Fulcrum Therapeutics Appoints Katina Dorton to its Board of DirectorsHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Fulcrum Therapeutics Appoints Katina Dorton to its Board of DirectorsGlobeNewswireJanuary 6, 2020ReblogShareTweetShareCAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the appointment of Katina Dorton to the Company’s board of directors and as chair of the audit committee.“We are excited to have Katina join the team,” said Robert J. Gould, Ph.D., Fulcrum’s president and chief executive officer. “Her appointment reflects our commitment to ensuring we have a broad mix of skills and perspectives on Fulcrum’s board. We look forward to benefiting from Katina’s guidance and leadership as we continue to make important progress with losmapimod and expand our pipeline.”Ms. Dorton most recently served as Executive Vice President and Chief Financial Officer at Repare Therapeutics, an oncology company focused on DNA damage repair and synthetic lethality, and prior to that, Chief Financial Officer at AVROBIO, a gene therapy company focused on rare disease. Previously, Ms. Dorton spent more than 15 years as an investment banker, advising companies and their Boards on capital markets, fund raising, mergers and acquisitions and other strategic transactions. She was a Managing Director at Morgan Stanley and a Managing Director at Needham & Co. She also served as an attorney in private practice at Sullivan & Cromwell. Ms. Dorton currently is on the Board of Directors at US Ecology, an environmental services company. Ms. Dorton holds a J.D. from the University of Virginia School of Law, an M.B.A. from George Washington University and a B.A. from Duke University.“Fulcrum’s unique approach to developing small molecule therapies that target the root cause of serious genetic disorders offers great promise to patients and their families,” said Ms. Dorton. “I look forward to working with the board and company leadership as Fulcrum advances its pipeline.”About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and has completed extensive pre-clinical research for FTX-6058 for the treatment of sickle cell disease and beta-thalassemia.Please visit www.fulcrumtx.com.Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in the Company’s most recent filings with the Securities and Exchange Commission.Investor Contacts:Christi WaarichDirector, Corporate Communications and Investor Relationscwaarich@fulcrumtx.com650-483-1970Stephanie Ascher Stern Investor Relations, Inc. stephanie.ascher@sternir.com212-362-1200Media Contact:
Lynn GranitoBerry & Company Public Relationslgranito@berrypr.com212-253-8881ReblogShareTweetShareRecently ViewedYour list is empty.What to Read Next5 Things You Should Know About Spinal Muscular AtrophyThe MightyCara Therapeutics (CARA) Reports Q4 Loss, Misses Revenue EstimatesZacksCytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue EstimatesZacksFive Prime Therapeutics (FPRX) Reports Q4 Loss, Misses Revenue EstimatesZacksRevance Therapeutics, Inc. Just Reported And Analysts Have Been Cutting Their EstimatesSimply Wall St.Richard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo Finance